Key points from article :
Inceptive, a Californian AI startup, secures $100M funding to advance its mRNA-based medicine design platform.
The company uses AI to design novel medicines previously out of reach.
Their goal is to offer this platform to organizations involved in the development of mRNA and RNA medicines.
The funding will enhance the capabilities of Inceptive's "biological software" platform.
Over 310 programs are in progress between pre-clinical and clinical trials.
Inceptive's co-founder aims to provide this as a horizontal capability to any entity developing mRNA and later RNA medicines.